The Endocannabinoid System and Related Lipids as Potential Targets for the Treatment of Migraine-related Pain

Rosaria Greco PhD; Chiara Demartini PhD; Anna Maria Zanaboni BSc; Miriam Francavilla MSc; Roberto De Icco MD, PhD; Lara Ahmad MD; Cristina Tassorelli MD, PhD


Headache. 2022;62(3):227-240. 

In This Article


The ECS is characterized by a high degree of heterogeneity and complexity, which makes it difficult to profile the individual effects of the different molecules and the receptors involved (i.e., CB1, CB2, TRPV1, and PPARs), and to define the modalities of its crosstalk with other pathways.

The preclinical advances in this field in recent decades have clearly confirmed that the ECS is involved in the modulation of migraine-related pain, but the road ahead is still long. Multiple molecules linked to the ECS have emerged as potential therapeutic targets. The complexity of the system demands caution and precise biochemical and pharmacological characterization of the new compounds to be tested and developed.